- Home
- STNG vs IDYA Comparison
STNG vs IDYA Comparison
Compare STNG & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STNG
- IDYA
- Stock Information
- Founded
- STNG 2009
- IDYA 2015
- Country
- STNG Monaco
- IDYA United States
- Employees
- STNG N/A
- IDYA N/A
- Industry
- STNG Marine Transportation
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- STNG Consumer Discretionary
- IDYA Health Care
- Exchange
- STNG Nasdaq
- IDYA Nasdaq
- Market Cap
- STNG 3.2B
- IDYA 2.8B
- IPO Year
- STNG 2010
- IDYA 2019
- Fundamental
- Price
- STNG $61.79
- IDYA $32.28
- Analyst Decision
- STNG Strong Buy
- IDYA Buy
- Analyst Count
- STNG 5
- IDYA 14
- Target Price
- STNG $69.00
- IDYA $49.58
- AVG Volume (30 Days)
- STNG 690.0K
- IDYA 1.1M
- Earning Date
- STNG 10-30-2025
- IDYA 11-04-2025
- Dividend Yield
- STNG 2.72%
- IDYA N/A
- EPS Growth
- STNG N/A
- IDYA N/A
- EPS
- STNG 5.88
- IDYA N/A
- Revenue
- STNG $889,539,000.00
- IDYA $214,834,000.00
- Revenue This Year
- STNG N/A
- IDYA $90.17
- Revenue Next Year
- STNG $3.05
- IDYA $217.29
- P/E Ratio
- STNG $10.52
- IDYA N/A
- Revenue Growth
- STNG N/A
- IDYA 5377.66
- 52 Week Low
- STNG $30.63
- IDYA $13.45
- 52 Week High
- STNG $65.52
- IDYA $33.64
- Technical
- Relative Strength Index (RSI)
- STNG 56.77
- IDYA 63.01
- Support Level
- STNG $61.28
- IDYA $30.26
- Resistance Level
- STNG $63.21
- IDYA $32.69
- Average True Range (ATR)
- STNG 2.08
- IDYA 1.41
- MACD
- STNG -0.13
- IDYA -0.03
- Stochastic Oscillator
- STNG 47.91
- IDYA 70.52
About STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.